Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ovarian Neoplasms

Free Subscription 08.08.2022 2 BMC Cancer 2 Clin Cancer Res 4 Gynecol Oncol 2 J Clin Oncol 3 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. ZHANG Y, Wu H, Yu Z, Li L, et al
   Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
   BMC Cancer. 2022;22:842.
   PubMed         Abstract available
   
   
2. BRAICU EI, Krause CL, Torsten U, Mecke H, et al
   HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
   BMC Cancer. 2022;22:831.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

3. SERRA V, Wang AT, Castroviejo-Bermejo M, Polanska UM, et al
   Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.
   Clin Cancer Res. 2022 Aug 3. pii: 707431. doi: 10.1158/1078-0432.CCR-22-0568.
   PubMed         Abstract available
   
   
4. LEE JM, Moore RG, Ghamande S, Park MS, et al
   Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
   Clin Cancer Res. 2022 Aug 2. pii: 707411. doi: 10.1158/1078-0432.CCR-21-1733.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

5. HOARE JI, Hockings H, Saxena J, Silva VL, et al
   A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
   Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
   PubMed         Abstract available
   
   
6. JOLY F, Fabbro M, Berton D, Lequesne J, et al
   Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
   Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
   PubMed         Abstract available
   
   
7. LIANG MI, Simons JL, Herbey I, Wall JA, et al
   Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
   Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
   PubMed         Abstract available
   
   
8. CHASE DM, Marin MR, Backes F, Han S, et al
   Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
   Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

9. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
   Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
   J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
   PubMed        
   
   
10. LI N, Zhang Y, Wang J, Zhu J, et al
    Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    J Clin Oncol. 2022;40:2436-2446.
    PubMed         Abstract available
    
    

    
    PLoS One

11. ALI FT, Soliman RM, Hassan NS, Ibrahim AM, et al
    Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer.
    PLoS One. 2022;17:e0272308.
    PubMed         Abstract available
    
    
12. SRIRAMKUMAR S, Metcalfe TX, Lai T, Zong X, et al
    Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
    PLoS One. 2022;17:e0271584.
    PubMed         Abstract available
    
    
13. HIEPP L, Mayr D, Gartner K, Schmoeckel E, et al
    Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas.
    PLoS One. 2022;17:e0271630.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

14. AKTORIES K
    Treatment of ovarian cancer with modified anthrax toxin.
    Proc Natl Acad Sci U S A. 2022;119:e2210179119.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: